TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
The role of thrombophilia testing in women with adverse pregnancy outcomes
Key Statistics
- 15% — Pregnancies with placenta-mediated complications
- £250.82 — Cost of full thrombophilia screen (NHS)
- ~40% — Women with heparin adverse effects
Don't-miss facts
-
Do not routinely test for inherited thrombophilia after RPL, FGR, severe PET, abruption or stillbirth — results do not alter management (SMFM Choosing Wisely 2016)
-
TIPPS: dalteparin no benefit (17.1% vs 18.9%), more minor bleeding (19.6% vs 9.2%)
-
ALIFE & SPIN: aspirin ± LMWH does not improve live birth in unexplained RPL; ALIFE live birth highest in placebo arm
-
Aspirin is the evidence-based intervention: 100–150 mg nocte, before 16 weeks — ↓severe PET 17%, ↓FGR 10%
-
LMWH still indicated for: APS antibodies, previous catastrophic APS, previous VTE — with haematology input
-
APS diagnosis needs positive serology on 2 occasions ≥12 weeks apart; first-line obstetric APS treatment = low-dose aspirin
-
Catastrophic APS: <1% of APS, 50% mortality — anticoagulation + high-dose steroids + plasma exchange
-
~80% of women with RPL have a successful next pregnancy regardless of treatment (HepASA) — use this when counselling
Trial verdicts at a glance
Negative for LMWH: ALIFE · SPIN · HABENOX · HepASA · HAPPY · TIPPS · HEPEPE · Farquharson
Positive/partial: Gris 2004 · Rey 2009 · Kupferminc 2011 · FRUIT (<34 weeks only, NNT 12) Awaited: ALIFE2 (target 776)
Abbreviation Key
- FVL — factor V Leiden mutation
- FDIU — intrauterine fetal death
- APC — activated protein C
- SGA — small for gestational age
- APL — antiphospholipid (antibodies)
- VTE — venous thromboembolism
- APS — antiphospholipid syndrome
- NNT — number needed to treat
- LMWH — low-molecular-weight heparin
- OR / RR — odds ratio / risk ratio
- RPL — recurrent pregnancy loss
- ESHRE — European Society of Human Reproduction and Embryology
- FGR — fetal growth restriction
- SMFM — Society for Maternal and Fetal Medicine
- PET — severe pre-eclampsia
Source: Unterscheider J, Kane SC, Cutts B, Savoia H, Said JM. The role of thrombophilia testing in women with adverse pregnancy outcomes. The Obstetrician & Gynaecologist 2017;19:163–72. doi:10.1111/tog.12366
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).